Kornimate/medical-research-clean huggingface dataset:
the comparison of electronic auscultation coupled with calsa and fri; repeatability of fri biomarkers

Conditions: Asthma

Summary: calsa will be compared with fri and the repeatability of the fri parameters will be tested in a group of healthy volunteers and asthma patients.

his is a study with no investigational product. calsa will be compared with fri and the repeatability of the fri parameters will be tested in a group of healthy volunteers and asthma patients. electronic auscultation of respiratory sounds will be performed, lung function tests (at maximal dilatation) will be executed and computed tomography (ct) scans of the thorax will be taken. the scans will be taken at two different breathing levels, more specifically at total lung capacity (tlc) and functional residual capacity (frc) level. the scans will be taken while the patient/ volunteer lies down on the movable table of the ct-scan. after the scan is taken it will be asked to the patient/ volunteer to sit upright on the scanning table and to lie down again. when the patient/ volunteer lies down a second ct-scan (tlc and frc) will be taken. the objective of this study is to compare calsa with fri and to assess the repeatability of fri biomarkers

Eligibility criteria:
inclusion criteria: * male or female patient / volunteer ≥ 18 years old * written informed consent obtained * the subject belongs to 1 of the following groups in the opinion of the investigator: group 1: healthy volunteer group 2: patient with asthma * only if patient/ volunteer is a female of childbearing potential: confirmation that a contraception method was used at least 14 days before visit 1 exclusion criteria: * pregnant or lactating female * patient/ volunteer with an uncontrolled disease or any condition that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study. patient/ volunteer with an uncontrolled disease or any condition that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study.
a study of ly2439821 in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the safety and tolerability of ly2439821 subcutaneously administered for 48 weeks in japanese participants with rheumatoid arthritis who have completed study i1f-je-rhal (nct01253265).


Eligibility criteria:
inclusion criteria: * participants who have received 7 injections of ly2439821 subcutaneously in the 30-, 80-, or 180-mg dose cohorts, or 11 injections in the 240-mg loading dose/120-mg once-a-week maintenance dose group, and completed the follow-up period (14 weeks) in study i1f-je-rhal ((nct01253265). * ambulatory male or female participants. * male participants: agree to use a reliable method of birth control during the study including barrier contraceptives or a monogamous relationship with a partner who is not child bearing. * female participants: are women who test negative for pregnancy at the time of entry based on a pregnancy test and are not breast feeding. women of child bearing potential must agree to use a reliable method of birth control during the study. * participants who have been treated with methotrexate (mtx) throughout study i1f-je-rhal (nct01253265). bucillamine, sulfasalazine and/or hydroxychloroquine are allowed to be administered in addition to mtx. in such a case, the participant needs to have been on a stable dose of the drug(s) throughout study i1f-je-rhal (nct01253265) and i1f-je-rham. * participants who have given written informed consent approved by the sponsor and the institutional review board (irb) governing the investigational site. exclusion criteria: * participants who have had, during study i1f-je-rhal (nct01253265), any safety event including having a recent, ongoing, or serious infection, a serious drug reaction, or any adverse event (ae) that caused discontinuation from treatment , that in the opinion of the investigator poses an unacceptable risk to participation in this study. * participants who have any of the following abnormalities of clinical laboratory test results by week 26 of study i1f-je-rhal (nct01253265): * absolute neutrophil count \<1000 cells/microliters (μl); * lymphocyte count \<500 cells/μl; or * white blood cells (wbc) count \<2000 cells/μl
chart review: unresectable/metastatic cholangiocarcinoma treated with irinotecan, capecitabine and celecoxib

Conditions: Cholangiocarcinoma

Summary: chart review on patients with unresectable/metastatic cholangiocarcinoma treated in the unm cancer center with a combination of irinotecan, capecitabine and celecoxib.

as above.

Eligibility criteria:
inclusion criteria: * patients with unresectable/metastatic cholangiocarcinoma treated in the unm cancer center with a combination of irinotecan, capecitabine and celecoxib. exclusion criteria: * not specified.

Keywords: unresectable/metastatic cholangiocarcinoma cancer chart review
ideal study: identification of the determinants of the efficacy of arterial blood pressure lowering drugs

Conditions: Hypertension

Summary: the principal scientific objective of the trial is to identify the factors that are associated with differential blood pressure responses between drugs. this may allow investigators to produce new hypotheses on the pathophysiology of hypertension and on the mechanisms of drug action. these factors can be of different types: * environmental factors (sodium or alcohol intake); * morphological (height, weight, body mass index, body surface area); * initial blood pressure; * electrocardiogram (ecg) parameters of left ventricular hypertrophy; * biological parameters as the activity level of the renin angiotensin aldosterone system; * genetic polymorphisms.


Eligibility criteria:
inclusion criteria: * participants have to be 25 to 60 years of age * both genders * systolic blood pressure of 140 mmhg or above; diastolic blood pressure of 90 mmhg or above. * cardiovascular risk must not be high, to allow for two periods of 4 weeks of placebo without ethical concern.

Keywords: hypertension - drugs - blood pressure response - responders - pharmacogenetics
protege extension trial - long term follow up trial for subjects who completed the protege study (cp-mga031-01)

Conditions: Type 1 Diabetes Mellitus

Summary: the purpose of this study is to assess the long term safety and efficacy in subjects with type 1 diabetes mellitus who completed the protege study (cp-mga031-01).

the primary objective of the extension study is to assess long-term safety, with particular focus on the development of serious adverse events (saes), adverse events of special interest (aesis) including opportunistic infections and lymphoproliferative disease, and other immediately reportable events (ires), in subjects with recent-onset t1dm who complete cp-mga031-01. the secondary objectives of the extension study are to: 1) assess long-term efficacy; 2) evaluate immunological effects(north america only); 3) measure anti-teplizumab antibody levels;4) assess health related quality of life questionnaires.

Eligibility criteria:
inclusion criteria: 1. complete protocol cp-mga031-01 (i.e., all subjects who complete study day 728, regardless of how many doses of study drug are received). 2. provide written informed consent. exclusion criteria: none

Keywords: teplizumab protege mga031 monoclonal antibody type 1 diabetes mellitus t1dm macrogenics
assessment of endothelial glycocalyx in patients with primary open-angle glaucoma

Conditions: Primary Open-angle Glaucoma; Glaucoma

Summary: the glycocalyx is a fibrillary lining structure that covers the inner surface of blood vessels. composed of glycoproteins and polysaccharides, it is an essential determinant of vascular endothelial physiology: it limits coagulation activation and adapts capillary perfusion. studies have shown glycocalyx alteration in various vascular and autoimmune pathologies such as diabetes, high blood pressure, chronic renal failure, ischemic heart disease, stroke, dementia, septic shock, and several other inflammatory pathologies with a common basis in vascular insufficiency. glaucoma is a progressive, chronic and asymptomatic optic neuropathy characterized by visual field damage and abnormalities of the optic nerve head. two hypotheses have been proposed as a basis for this progressive damage: * the mechanical theory, which explains the papillary excavation by a compression of the optic nerve head under the effect of high intraocular pressure; and * the ischemic theory, explained by a circulatory insufficiency at the level of the blood capillaries of the retina and especially of the optic nerve head. this latter theory is related to several pathologies that have circulatory insufficiency as common underlying pathophysiology, and in which damage to the glycocalyx has been well studied. glycocalyx damage has rarely been studied in glaucoma. yang et al. showed that the glycocalyx, present in schlem's canal, plays a major role in the transduction of shear stress and regulation of outflow resistance to the aqueous humor, which may constitute an interesting biomarker for glaucomatous pathologies.

this study propose to extend the exploration of the ischemic theory of glaucoma by a specific imaging technique (the glycocheck) which allows an assessment of the microvascular system integrity by giving a "vitality score" of this system. this score, known as the microvascular health score (mvhs), depends on the following measured parameters: capillary density (cd), red blood cell filling percent (rbf), and perfused boundary region (pbr).

Eligibility criteria:
inclusion criteria: * express consent to participate in the study * only for case group: primary open angle glaucoma (defined as the presence of visual field damage attributed to glaucomatous optic neuropathy) in both eyes * only for control group: absence optic nerve pathology (including primary open angle glaucoma) exclusion criteria: * pregnant or breastfeeding woman * sleep apnea * renal insufficiency * parkinson's disease * alzheimer's disease * antiphospholipid syndrome * cancer for which treatment ended less than 2 years ago * stroke less than 1 year ago * myocardial infarction less than 1 year ago

Keywords: glycocheck sublingual microvascularization glycocalyx primary open-angle glaucoma glaucoma
effectiveness of extracorporeal shockwave therapy and nutraceutical supplementation in the treatment of epicondylitis: a clinical trial

Conditions: Epicondylitis, Lateral; Epicondylitis of the Elbow; Tennis Elbow

Summary: lateral epicondylitis is a pathologic condition of the musculotendinous system, characterized by the presence of pain at the lateral epicondyle of the humerus; it is a tendinopathy of the extensor muscles of the forearm, often caused by overuse or repetitive use of the arm, forced extension of the elbow, or direct trauma to the humeral epicondyle. this study evaluated the efficacy of extracorporeal shockwave treatment (eswt) combined with a supplemental nutraceutical treatment of hyaluronic acid, collagen, vitamin c, and manganese, compared with single treatment in patients with lateral epicondylitis in term of improvement in pain, functional capacity, muscle strength, and reduction of inflammation on ultrasound images. a clinical trial was conducted at the u.o.c. of "recovery and functional rehabilitation" of a.o.u.p. "p. giaccone" of palermo from marc 2024 to july 2024. patients were randomized into 3 groups: in group "a", n° 5 sessions of focal eswt were given every six days; in group "b", patients took daily for 30 days, supplemental nutraceutical treatment of hyaluronic acid, collagen, vitamin c, and manganese; and group "c", patients had combined treatment of eswt (one session every six days for a total of five sessions) and nutraceutical supplementation (one administration per day for one month). all patients were evaluated at enrollment (t0), after one month, at the end of rehabilitation treatment (t1), and at a follow up 30 days after the end of treatment (t2). researched will compare patients treated with eswt or with nutraceutical treatment, and patients who had combined treatment to see if there are real differences in term of pain reduction and improved short- and long-term quality of life.


Eligibility criteria:
inclusion criteria: * diagnosis of lateral epicondylitis; * ultrasound evidence of inflammatory status of the tendon of the wrist common extensor muscle; * numerical rating scale (nrs) at t0 ≥ 4; * pharmacological wash out starting seven days before treatment; * written informed consent. exclusion criteria: * pregnancy; * already diagnosed or diagnostically defined neoplasms; * pacemaker wearers; * coagulation disorders and/or anticoagulant therapy; * skin lesions and/or local infections; * tendon injury and/or previous surgery on the wrist extensor tendons; * cervical myelopathy; * epilepsy; * patients with contraindications and/or allergies to the active ingredients of nutracetical supplementation; * obesity with bmi\&gt;30 (kg/m2).

Keywords: epicondylitis extracorporeal shockwave treatment (eswt) nutraceutical supplementation rehabilitation musculoskeletal disease tendinopathy tennis elbow
pharmacokinetics and pharmacodynamics of sugammadex in reversal of vecuronium-induced neuromuscular blockade

Conditions: Pharmacokinetics; Pharmacodynamics

Summary: the purpose of this study is to illustrate pharmacokinetics and pharmacodynamics of sugammadex in reversal of vecuronium-induced neuromuscular blockade in anesthesia obese patients undergoing bariatric surgery.

16 obese patients undergoing bariatric surgery were divided into 2 groups according to body mass index (bmi), including obese group (o group, n=8, 25≤bmi≤39.9kg/m²) and morbidly obese group (m group, n=8, bmi≥40kg/m²). vecuronium was continuous infusing to maintain moderate neuromuscular blockade during the laparoscopic surgery and stopped infusing after the laparoscopic procedure. a single dose administration of sugammadex (sug) 2.0mg/kg according to ideal body weight (ibw) was given at the reappearance of the second twitch of the train-of-four (tof) response. on one hand, venous blood samples were obtained before administration of sug and at 2, 3, 5, 10, 15, 20, 30, 60 minutes and 2, 4, 6, 8 hours after administration of sug to determine plasma concentration of sug using hplc-ms. on the other hand, time from start of administration of sug to recovery of tof ratio to 0.9 and other clinical indicators were also recorded.

Eligibility criteria:
inclusion criteria: * asa: ⅰ\~ⅲ * bmi≥25kg/m² * patients receiving bariatric surgery. exclusion criteria: * pregnant or lactating women * neuromuscular diseases * malignant hyperthermia or allergic history during general anesthesia * drugs that react with rocuronium and vecuronium were taken

Keywords: sugammadex obese
association of biliary tract disorders in chronic kidney disease patients and its related risk factors

Conditions: CKD; Gall Bladder Dysfunction

Summary: our aim in this cross-sectional study is to determine the frequency and aspects of gallbladder dysfunction and the related risk factors in pre-esrd and hemodialysis patients.

biliary tract disorders including cholelithiasis, cholecystitis, and other diseases of the biliary tract, are one of the most prevalent medical issues in the digestive system, posing a myriad of challenges for health workers and patients. gallbladder dysfunction is the most frequent cause of symptomatic and complicated biliary tract disorders. although gallbladder dysfunction is a common condition in middle east countries, data on the incidence of end-stage renal disease (esrd) are limited. the occurrence of gallbladder dysfunction in patients fed with low-protein diets suggests that gallbladder stones formation is affected by dietary protein content. also the lithogenic composition changes of bile, increased nucleation tendency, and impaired motility of gallbladder are important factors in esrd patients. it has been reported that chronic kidney disease (ckd) patients on regular hemodialysis (hd) have increased bile cholesterol levels and an increased bile saturation index. in addition, the gallbladder is innervated by the autonomic nervous system, which malfunctions in uremia, and it has been shown that gallbladder stasis might cause increased stone formation. in some studies, the prevalence of gallbladder dysfunction has been shown to increase in patients undergoing hemodialysis (hd) treatment for esrd. so, we focused in this study to try to find association of gallbladder dysfunction in pre-dialysis esrd and hd patient in comparison to normal renal function individuals.

Eligibility criteria:
inclusion criteria: * patients who are diagnosed as ckd with egfr according to cockcroft-gault equation, whatever they are on regular hemodialysis or pre-dialysis without history of previous gallbladder dysfunction with normal renal function individuals. exclusion criteria: * patients who are younger than 18 years. * patients who are diabetic. * patients who have body mass index (bmi) more than 30. * patients who have family history of gallbladder disorder.

Keywords: ckd gall bladder dysfunction gall bladder ejection fraction hemodialysis
innovation research of differentiation and treatment methods based on chd phlegm and blood stasis syndrome

Conditions: Coronary Heart Disease

Summary: coronary heart disease is still the major cause of death in china. chinese medicine plays more and more important role in chd prevention and treatment. phlegm and blood stasis are its major pathological basis. based on that, the investigator aims to evaluate the evolutionary process of chd phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method so as to guide the clinical treatment of chd.

coronary heart disease (chd) is a major cause of myocardial infarct (mi) and death induced by atherosclerosis or coronary artery spasm. despite improvements in interventional and pharmacological therapy for acute mi, the mortality early after ami remains high. nowadays, as our life quality develops and dietary structure changes, the morbidity of hyperlipidemia dramatically increased. based on the chinese medicine, hyperlipidemia belongs to phlegm and it's the basis of atherosclerosis, blood-stasis is the pathological basis of ischemia. therefore, the investigator proposes that phlegm and blood-stasis syndrome is the main differentiation on chd. based on that, the investigator prospectively and retrospectively explores the evolutionary process of chd phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method.it will provide evidence and guidance to the future clinical treatment using chinese medicine.

Eligibility criteria:
inclusion criteria: * healthy or metabolism syndrome people * clinical diagnosis of chd stable stage or acute coronary disease or chd heart failure exclusion criteria: * any inflammation, fever, trauma, burn or operation within 1 week * obstructive pulmonary disease * cerebral vascular disease * severe renal or hepatic dysfunction * malignant neoplasms * hematopoietic system disease * sever mental disease
a study of galunisertib in participants with myelodysplastic syndromes

Conditions: Myelodysplastic Syndromes

Summary: the purpose of this study is to investigate the effect of the study drug known as galunisertib in participants with myelodysplastic syndromes (mds). participants with different degrees of disease (very low, low, and intermediate risk) will be studied. the study treatment is expected to last about 6 months for each participant.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of mds based on the world health organization (who) criteria * participants with 5q deletions are allowed only if they have failed or are intolerant of lenalidomide treatment * participants must have a revised international prognostic scoring system (ipss-r) category of very low-, low-, or intermediate-risk disease * in the 8 weeks prior to registration, participants in phase 2 should have anemia with hb ≤10.0 g/dl (based on the average of 2 baseline measurements and untransfused for at least 1 week) with or without red blood cell (rbc) transfusion dependence confirmed for a minimum of 8 weeks before enrollment * for phase 3, participants should have anemia with rbc transfusion dependence confirmed within 8 weeks before enrollment * performance status ≤2 on the eastern cooperative oncology group (ecog) scale exclusion criteria: * no history of moderate or severe cardiac disease * no prior history of acute myeloid leukemia (aml)
effects of transcutaneous vagus nerve stimulation on recovery

Conditions: Fatigue; Recovery, Psychological

Summary: during the recovery process, the activity of the sympathetic system decreases, while the activity of the parasympathetic system increases. in line with this information, the nervous system can be regulated in a noninvasive and practical way by using transcutaneous auricular vagus nerve stimulation in order to achieve rapid recovery in the athlete after the activity.

in sports where physical loads are high, athletes can usually participate in more than one training or race during the day. such work increases the athlete's fatigue, affects their performance and can cause serious declines. therefore, an efficient and effective recovery process after high-intensity work and training that causes a decrease in performance is also very important for the athlete's next performance. with the start of sports activity or exercise, sympathetic activation in the body increases and after a while reaches a plateau value at maximum activity. with the end of exercise, this time the suppressed parasympathetic activity begins to increase and the sympathetic system returns to a resting state over time. there are insufficient studies in the literature investigating the use of transcutaneous auricular vagus nerve stimulation on the athletic population. although it is clear that the application has effects on the sympathetic and parasympathetic nervous systems, more clinical research is needed on athletes. in this study, we aimed to investigate the effects of auricular vagus nerve stimulation (vns) on vagal activity by examining the effect of transcutaneous auricular vagus nerve stimulation on recovery in amateur athletes through applications such as pulse and spo2, blood pressure, perceived fatigue, and respiratory function tests.

Eligibility criteria:
inclusion criteria: * being healthy between the ages of 18-25, * volunteering to participate in the study, * signing the voluntary consent form, * being an amateur football player who continues his/her active sports life, * not having an injury that prevents participation in the study. exclusion criteria: * having a disease related to the respiratory system, * having a disease related to the cardiac system, * having any chronic disease and using a medication related to it.

Keywords: auricular vagus nerve stimulation athlete recovery